This is a knockout-validated antibody summary, based on the publication "Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

[enlarge]

Figure 1. Single-cell clones of the complete ELP5 knockout (ELP5−/−) in two GBC cell lines, NOZ and GBC-SD, were generated using CRISPR/Cas9. The wild-type (WT) cells were transfected with the same vector carrying non-specific control sgRNA. From [1].

Mouse monoclonal IgG2a (kappa light chain)

Company: Santa Cruz

Antibody: DERP6

Catalog number: sc-514018

Summary: Mouse monoclonal IgG2a (kappa light chain) against amino acids 16-128 mapping near the N-terminus of human DERP6 (ELP5). Recommended for detection of DERP6 of mouse, rat and human origin by western blot, immunoprecipitation, immunofluorescence and ELISA.

Western blot

Control and ELP5-KO gallbladder cancer cell lines. Cell lysates were prepared in radioimmunoprecipitation lysis buffer (50 mm Tris, pH 7.4, 150 mm NaCl, 1% NP-40, 0.1% sodium dodecyl sulphate (SDS), 2 µm EDTA) containing proteinase inhibitor.

5% skim milk at room temperature for 1 h.

1:100 dilution at 4 °C overnight.

Horseradish peroxidase conjugated.

Signals were detected using the ECL Kit (Millipore).